USPSTF draft backs breast-cancer prevention drugs when risk is high

04/15/2013 | Reuters · · AAFP News Now

The U.S. Preventive Services Task Force released draft guidelines urging providers to discuss with appropriate female patients the benefits and dangers of drugs that could reduce breast cancer risks. Providers should offer tamoxifen or raloxifene in cases of increased risk of breast cancer and when side effects appear unlikely. "As family physicians, we need to be prepared to have those discussions with our patients, and that means being familiar with risk assessment tools," said USPSTF member Mark Ebell, M.D.

View Full Article in:

Reuters · · AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL